Theorem Clinical Research and Biomedical Systems Form Strategic Partnership to Expand Contract Services
(King of Prussia, PA; St. Louis, MO; Feb. 17, 2015) - Theorem Clinical Research, a prominent global contract research organization, and Biomedical Systems, a leading provider of comprehensive centralized diagnostic services, have formed a strategic partnership to expand the suite of services available to clients worldwide.
“Theorem’s business strategy is to offer our clients the very best available services in every research area,” said John Potthoff, Theorem president and CEO. “Biomedical Systems is one of the true pioneers in our industry, supervising breakthrough research innovations in centralized cardiac safety, pulmonary function, imaging, scientific affairs and electronic clinical outcome assessment (eCOA). The company’s broad range of capabilities and global scale are a complement to Theorem studies being conducted around the world.”
Headquartered in St. Louis, Biomedical Systems also has a European office in Brussels, with logistical support facilities in Japan and India and investigative sites in almost 100 countries. Theorem Clinical Research has offices in more than 30 countries worldwide, offering deep expertise in a broad range of therapeutic areas and all phases of development.
“The right strategic alliance strengthens both companies, empowering us both to offer enhanced services to our clients,” said Tim Barrett, CEO of Biomedical Systems. “We believe this alliance with Theorem creates a synergy that will be a benefit to all.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
